Voyager Therapeutics, Inc.

General ticker "VYGR" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $369.3M (TTM average)

Voyager Therapeutics, Inc. follows the US Stock Market performance with the rate: 0.7%.

Estimated limits based on current volatility of 2.6%: low 3.38$, high 3.57$

Factors to consider:

  • Earnings expected soon, date: 2025-05-12 bmo
  • Current price 20.3% below estimated low

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [4.08$, 8.79$]
  • 2025-12-31 to 2026-12-31 estimated range: [4.25$, 8.89$]

Financial Metrics affecting the VYGR estimates:

  • Negative: Non-GAAP EPS, $ of -1.13 <= 0.04
  • Negative: negative Operating income
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -4.12 <= 1.79
  • Positive: -3.20 < Investing cash flow per share, $ of -1.64
  • Positive: Interest expense per share, $ of 0 <= 0
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82

Similar symbols

Short-term VYGR quotes

2025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-022025-05-052025-05-062.833.23.43.63.8
Price $

Long-term VYGR plot with estimates

468101214Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−0.500.51
VYGRS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $40.91MM $250.01MM $80.00MM
Operating Expenses $91.74MM $127.99MM $163.29MM
Operating Income $-50.84MM $122.01MM $-83.29MM
Non-Operating Income $4.45MM $11.72MM $18.95MM
R&D Expense $60.76MM $92.17MM $127.37MM
Income(Loss) $-46.39MM $133.74MM $-64.34MM
Taxes $0.02MM $1.41MM $0.67MM
Profit(Loss)* $-46.41MM $132.33MM $-65.00MM
Stockholders Equity $59.02MM $236.32MM $299.76MM
Inventory $0.78MM $0.00MM $0.00MM
Assets $159.36MM $351.28MM $393.05MM
Operating Cash Flow $-12.51MM $77.92MM $-15.31MM
Capital expenditure $2.49MM $3.26MM $3.52MM
Investing Cash Flow $-7.34MM $-141.64MM $-94.86MM
Financing Cash Flow $1.11MM $33.65MM $114.02MM
Earnings Per Share** $-1.21 $3.08 $-1.13

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.